Ingrid Vasova

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

Journal: medRxiv : the preprint server for health sciences
Published: July 29, 2026

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Journal: Blood immunology & cellular therapy
Published: May 15, 2026

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

Journal: Med (New York, N.Y.)
Published: December 03, 2025

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

Journal: Nature medicine
Published: September 30, 2025

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.

Journal: The Lancet. Rheumatology
Published: July 23, 2025

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.

Journal: Blood advances
Published: May 09, 2025

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.

Journal: The Lancet. Rheumatology
Published: February 19, 2025

Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.

Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.

Journal: Blood advances
Published: February 14, 2025

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD.

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD.

Journal: Blood
Published: October 15, 2024

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.

Journal: Transplantation and cellular therapy
Published: September 09, 2024

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.

Journal: Transplantation and cellular therapy
Published: June 26, 2024

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.

Journal: Blood
Published: April 26, 2024
Showing 1-12 of 20

Last Updated: 09/26/2026